Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

8.5K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.5K
Endocrine Signaling01:45

Endocrine Signaling

66.1K
Endocrine cells produce hormones to communicate with remote target cells found in other organs. The hormone reaches these distant areas using the circulatory system. This exposes the whole organism to the hormone but only those cells expressing hormone receptors or target cells are affected. Thus, endocrine signaling induces slow responses from its target cells but these effects also last longer.
66.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Advances in diabetes technology: clinical implications, limitations, and future perspectives.

Hormones (Athens, Greece)·2026
Same author

Voice Changes in Laryngeal Intraepithelial Neoplasia and Nonneoplastic Lesions.

Journal of voice : official journal of the Voice Foundation·2026
Same author

Transoral Ultrasound in the Diagnostic Workup of Peritonsillar Abscess-A Randomized Clinical Trial.

The Laryngoscope·2026
Same author

Quantifying the efficacy-effectiveness gap in first line treatment of metastatic melanoma.

Journal of the National Cancer Institute·2026
Same author

Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Corrigendum to "Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma" [Eur J Cancer 234 (2026) 116200].

European journal of cancer (Oxford, England : 1990)·2026

Related Experiment Video

Updated: Nov 10, 2025

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.2K

Multiple endocrine neoplasia type 2: A review.

Jes Sloth Mathiesen1, Grigoris Effraimidis2, Maria Rossing3

  • 1Department of ORL Head & Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

Seminars in Cancer Biology
|April 4, 2021
PubMed
Summary

Multiple endocrine neoplasia type 2 (MEN 2) is a hereditary cancer syndrome caused by RET gene variants. Understanding genotype-phenotype links improves patient risk classification and management through genetic counseling.

Keywords:
Genotype-phenotypeMEN 2Medullary thyroid carcinomaPrognosisProphylactic thyroidectomyRisk stratification

More Related Videos

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
12:04

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy

Published on: August 14, 2012

29.2K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.4K

Related Experiment Videos

Last Updated: Nov 10, 2025

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.2K
Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
12:04

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy

Published on: August 14, 2012

29.2K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.4K

Area of Science:

  • Genetics
  • Oncology
  • Endocrinology

Background:

  • Multiple endocrine neoplasias (MEN) are rare hereditary syndromes with malignant potential.
  • MEN type 2 (MEN 2) arises from germline variants in the REarranged during Transfection (RET) proto-oncogene, presenting as MEN 2A or MEN 2B.
  • MEN 2A and MEN 2B involve distinct clinical manifestations including medullary thyroid carcinoma and phaeochromocytoma.

Purpose of the Study:

  • To review recent advancements in understanding MEN 2 hereditary syndromes.
  • To summarize the impact of these advancements on clinical management and genetic counseling.
  • To identify future research directions for optimizing patient survival and reducing morbidity.

Main Methods:

  • Review of current literature on MEN 2 genetics and clinical presentations.
  • Analysis of genotype-phenotype associations and their impact on risk stratification.
  • Synthesis of information regarding genetic counseling and patient management strategies.

Main Results:

  • Germline RET variants in MEN 2 lead to a gain-of-function, explaining the syndrome's hereditary nature.
  • Genotype-phenotype association studies have enhanced risk classification and improved patient prognosis.
  • Genetic counseling is crucial for managing individual patients and affected families.

Conclusions:

  • Understanding RET proto-oncogene variants significantly improves MEN 2 patient management.
  • Further research is needed to refine treatment timing for various MEN 2 manifestations.
  • Optimizing management strategies aims to enhance survival rates and decrease morbidity in MEN 2 patients.